RYAH’s IoT Devices Can Deliver Psychedelic Medicines, Advance the Industry
September 30th, 2021
News, Top Story
In the emerging world of psychedelic medicine, there is an urgent need to document, quantify, and qualify the efficacy of treatments. The process is underway. This summer there were at least 56 clinical trials recruiting participants, with more already started and more to come. Conditions targeted by these trials range from depression to anorexia, from headaches to addiction. There is a lot to learn and a lot of data to be produced, collated, and analyzed. Market estimates vary, and future growth is certainly dependent on the success or failure of these clinical trials. According to analysts Research and Markets, the global psychedelic drugs market was valued at $3.8 billion in 2020 and is expected to nearly double to $7.58 billion in 2026, representing a robust 13.3% CAGR.
One company with an interesting angle into the market is RYAH Group, Inc. (CSE: RYAH). RYAH specializes in plant medicine without ever touching the medicine. Rather, the company makes smart delivery devices like inhalers and patches and pens that are capable of delivering all manner of medicines, including psychedelics, in precisely controlled doses. The devices are connected to the RYAH Cloud and patented AI-powered data engine, which can make treatment recommendations and create insights gathered from a vast amount of data. RYAH brings Internet of Things (IoT) technology to plant medicine.
Click here to receive an investor presentation and corporate updates
RYAH’s database, assembled by input from over 200,000 registered users, is already the world’s largest gathering of plant medicine data. The company’s devices are being used in medical cannabis trials around the world. Now, RYAH is investigating the utility of its system in the burgeoning realm of psychedelic research and so far it looks promising.
Data, Technology, and Psychedelics
Data and technology play such an important role in the development and acceptance of psychedelics as medicine that there is an upcoming industry conference dedicated to the subject. In advance of October’s PSYCH Investor Summit: Data and Technology, the organizers at Psych Capital interviewed RYAH Group CEO Gregory Wagner about the company’s IoT platform and its capabilities in the space.
In the interview, Wagner states, ‘A lot of our peers create brilliant devices, but do not offer related viable data analytics. Other data companies have great data analytics platforms that involve scraping large volume of data off of the web, but no devices to obtain specific patient activities and feedback. We pride ourselves on capturing captive patient session data and analytics. There is an old saying that you either mine for gold, or sell the pickaxes. We do both, we have the pickaxes (or devices), and we have the gold to mine. We believe that data is the gold.’
The ability for doctor’s and clinics to have the tools to create a customized and personalized precise dosing regimen is crucial to the application of psychedelics as medicine. The ability to easily track patient experiences and compare them to other patient experiences is crucial as well. The ability to gather and analyze data from a large variety of disparate sources can help move the industry forward more quickly and efficiently. RYAH’s platform does it all seamlessly.
And RYAH is liking what it is seeing so far in terms of compatibility with and interest from the psychedelic medicine space. “This is a space where the lines of ‘adult use’ (recreational) and medical lines are not blurred. The psychedelic space is expected to be a purely medical administration for quite some time. RYAH’s aspiration is a medical one, so we see our devices and data analytics becoming an integral part of alternative medicine therapies such as psychedelic treatment regimens.”
What to Watch For
RYAH has had great success in penetrating the medical cannabis industry, with international partnerships and studies feeding it’s constantly expanding database of patient experiences, dosing regimens, strain profiles, and treatment options. Consider the psychedelic medicine space as a parallel and complementary track for the company as it explores potential deals and partnerships in the space. RYAH has just started ‘dating’ in the psychedelic industry, but prospects for solid relationships look good at this point. Stay tuned.
Click here to receive an investor presentation and corporate updates
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.